Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Current Liabilities (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Total Current Liabilities readings, the most recent being $743.4 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 46.43% to $743.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $743.4 million, a 46.43% increase, with the full-year FY2025 number at $743.4 million, up 46.43% from a year prior.
  • Total Current Liabilities hit $743.4 million in Q4 2025 for Neurocrine Biosciences, up from $638.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $743.4 million in Q4 2025 to a low of $190.0 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $496.4 million (2022), compared with a mean of $462.0 million.
  • Biggest five-year swings in Total Current Liabilities: plummeted 63.03% in 2021 and later skyrocketed 118.76% in 2022.
  • Neurocrine Biosciences' Total Current Liabilities stood at $245.8 million in 2021, then skyrocketed by 118.76% to $537.7 million in 2022, then grew by 21.78% to $654.8 million in 2023, then decreased by 22.46% to $507.7 million in 2024, then skyrocketed by 46.43% to $743.4 million in 2025.
  • The last three reported values for Total Current Liabilities were $743.4 million (Q4 2025), $638.0 million (Q3 2025), and $546.3 million (Q2 2025) per Business Quant data.